Professor Andrew Spencer is Head of the Malignant Haematology, Transplantation and Cellular Therapy Service at The Alfred Hospital, Professor of Haematology at Monash University and Head of the Myeloma Research Group (MRG), all in Melbourne, Australia. He leads an independent translational research program and a first-in-human and early phase clinical research unit with currently over 190 open trials with >900 registered trial patients. He has >320 peer reviewed publications with over 30,000 citations and a 10-year FWCI of 4.17. Since 2019 he has been an invited speaker at 50 international meetings on genomics, therapeutics and disease monitoring in myeloma and is an invited investigator of the International Myeloma Foundation (IMF) Black Swan Research Initiative with a focus on liquid biopsy approaches. He serves on the scientific advisory boards of the IMF and the International Myeloma Working Group. He established and Chairs the ANZ Myeloma and Related Diseases Registry (MRDR), the APAC MRDR and the associated M1000 liquid biopsy biobank. He established the Australasian Myeloma Research Consortium (AMaRC) in 2016.